BR112017017729A2 - forma de dosagem oral de liberação controlada de agonista de receptor gaba - Google Patents
forma de dosagem oral de liberação controlada de agonista de receptor gabaInfo
- Publication number
- BR112017017729A2 BR112017017729A2 BR112017017729A BR112017017729A BR112017017729A2 BR 112017017729 A2 BR112017017729 A2 BR 112017017729A2 BR 112017017729 A BR112017017729 A BR 112017017729A BR 112017017729 A BR112017017729 A BR 112017017729A BR 112017017729 A2 BR112017017729 A2 BR 112017017729A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor agonist
- controlled release
- dosage form
- oral dosage
- release oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Abstract
a presente invenção refere-se a uma forma de dose simples e melhorada que é capaz de fornecer uma liberação controlada de agonista de receptor gabab contida do mesmo no núcleo. a invenção da mesma forma fornece métodos de administrar a forma de dosagem e de condições de tratamento que são terapeuticamente responsivos para agonista de receptor gabab.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562118910P | 2015-02-20 | 2015-02-20 | |
US201562119017P | 2015-02-20 | 2015-02-20 | |
US201562130757P | 2015-03-10 | 2015-03-10 | |
US201562131495P | 2015-03-11 | 2015-03-11 | |
PCT/IB2016/000260 WO2016132220A1 (en) | 2015-02-20 | 2016-02-19 | Controlled release oral dosage form of gaba receptor agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017017729A2 true BR112017017729A2 (pt) | 2018-04-10 |
Family
ID=55637392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017017729A BR112017017729A2 (pt) | 2015-02-20 | 2016-02-19 | forma de dosagem oral de liberação controlada de agonista de receptor gaba |
Country Status (4)
Country | Link |
---|---|
US (8) | US9579289B2 (pt) |
EP (2) | EP3258914A1 (pt) |
BR (1) | BR112017017729A2 (pt) |
WO (4) | WO2016132233A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579289B2 (en) | 2015-02-20 | 2017-02-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
MX2020010909A (es) * | 2018-04-17 | 2020-11-06 | Poviva Corp | Composiciones infundidas con agentes activos lipofilicos que tienen efecto alimentario reducido. |
CN109966281B (zh) * | 2019-04-11 | 2021-04-27 | 北京大学 | PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用 |
BR112022006802A2 (pt) | 2019-10-08 | 2022-08-16 | Bayer Healthcare Llc | Cápsulas gravadas a laser e métodos de fabricação das mesmas |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (pt) | 1960-11-29 | |||
US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3699103A (en) | 1970-10-07 | 1972-10-17 | Hoffmann La Roche | Process for the manufacture of 5-desoxy-l-arabinose and novel intermediates |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3926891A (en) | 1974-03-13 | 1975-12-16 | Dow Chemical Co | Method for making a crosslinkable aqueous solution which is useful to form soft, water-swellable polyacrylate articles |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4016880A (en) | 1976-03-04 | 1977-04-12 | Alza Corporation | Osmotically driven active agent dispenser |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4615698A (en) | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
ATE72111T1 (de) | 1987-01-14 | 1992-02-15 | Ciba Geigy Ag | Therapeutisches system fuer schwerloesliche wirkstoffe. |
US4801461A (en) | 1987-01-28 | 1989-01-31 | Alza Corporation | Pseudoephedrine dosage form |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
EP0655970B1 (en) | 1992-08-17 | 2002-10-09 | Weyerhaeuser Company | Particle binding to fibers |
US5558879A (en) | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AR026148A1 (es) | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | Dispositivo osmotico con pasaje preformado que aumenta de tamano |
ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6632217B2 (en) | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
US6809288B2 (en) | 2001-05-23 | 2004-10-26 | Osmotica Corp. | Laser drilling system and method |
AU2002355686B2 (en) | 2001-07-04 | 2007-11-29 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
WO2004091521A2 (en) | 2003-04-10 | 2004-10-28 | Neurogesx, Inc. | Methods and compositions for administration of trpv1 agonists |
US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
UY28326A1 (es) | 2003-05-22 | 2004-06-30 | Osmotica Argentina S A | Dispositivo de ruptura de liberacion controlada con un pasaje preformado |
US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
US20050090554A1 (en) | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
US20050220873A1 (en) | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
US20050226927A1 (en) | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
US8007827B2 (en) | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
US8574626B2 (en) * | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
AU2007201808B8 (en) | 2006-04-26 | 2013-09-05 | Sun Pharmaceutical Advanced Research Company Ltd | A method for alleviating signs and symptoms of spasticity |
CN100584319C (zh) | 2006-10-16 | 2010-01-27 | 北京科信必成医药科技发展有限公司 | 群孔释放渗透泵控释片及其制备方法 |
LT2083811T (lt) | 2006-11-22 | 2017-01-25 | Clinical Research Associates, Llc | Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai |
JP2010515754A (ja) | 2007-01-11 | 2010-05-13 | ゼノポート,インコーポレイティド | R−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法 |
TW200908957A (en) | 2007-06-15 | 2009-03-01 | Xenoport Inc | Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity |
US8637080B2 (en) | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
TW200936123A (en) * | 2007-11-06 | 2009-09-01 | Xenoport Inc | Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain |
US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
ITUD20080064A1 (it) | 2008-03-26 | 2009-09-27 | Levinvest S P A | Macchina e procedimento per la produzione di fibra metallica |
WO2009158625A2 (en) | 2008-06-26 | 2009-12-30 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
PL2378883T3 (pl) | 2008-12-04 | 2016-06-30 | Intec Pharma Ltd | SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU |
EP2403486A1 (en) * | 2009-03-03 | 2012-01-11 | XenoPort, Inc. | Sustained release oral dosage forms of an r-baclofen prodrug |
CA2790164A1 (en) | 2010-02-17 | 2011-08-25 | Sun Pharma Advanced Research Company Ltd. | Method of treating a disease condition susceptible to baclofen therapy |
AU2011271429B2 (en) | 2010-06-30 | 2016-04-21 | Upsher-Smith Laboratories, Llc | Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid |
US8580850B2 (en) | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
US9579289B2 (en) | 2015-02-20 | 2017-02-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
-
2016
- 2016-02-19 US US15/048,743 patent/US9579289B2/en active Active
- 2016-02-19 WO PCT/IB2016/000438 patent/WO2016132233A1/en active Application Filing
- 2016-02-19 WO PCT/IB2016/000260 patent/WO2016132220A1/en active Application Filing
- 2016-02-19 WO PCT/IB2016/000232 patent/WO2016132218A1/en active Application Filing
- 2016-02-19 EP EP16713980.7A patent/EP3258914A1/en active Pending
- 2016-02-19 BR BR112017017729A patent/BR112017017729A2/pt not_active Application Discontinuation
- 2016-02-19 EP EP16716675.0A patent/EP3258916A1/en not_active Withdrawn
- 2016-02-19 WO PCT/IB2016/000230 patent/WO2016132217A1/en active Application Filing
- 2016-04-19 US US15/132,972 patent/US9585843B2/en active Active
- 2016-05-04 US US15/146,525 patent/US9655858B2/en active Active
-
2017
- 2017-04-20 US US15/492,714 patent/US9801841B2/en active Active
- 2017-08-10 US US15/673,985 patent/US10213402B2/en active Active
-
2018
- 2018-03-13 US US15/919,436 patent/US10213404B2/en active Active
- 2018-03-13 US US15/919,422 patent/US10213403B2/en active Active
-
2019
- 2019-02-08 US US16/270,837 patent/US10471031B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3258916A1 (en) | 2017-12-27 |
WO2016132220A1 (en) | 2016-08-25 |
US9655858B2 (en) | 2017-05-23 |
US20160243067A1 (en) | 2016-08-25 |
EP3258914A1 (en) | 2017-12-27 |
US10213402B2 (en) | 2019-02-26 |
US10213404B2 (en) | 2019-02-26 |
US20190167618A1 (en) | 2019-06-06 |
US9801841B2 (en) | 2017-10-31 |
WO2016132233A1 (en) | 2016-08-25 |
US20170216236A1 (en) | 2017-08-03 |
US20180200215A1 (en) | 2018-07-19 |
US9579289B2 (en) | 2017-02-28 |
US20170340592A1 (en) | 2017-11-30 |
US20180200214A1 (en) | 2018-07-19 |
US9585843B2 (en) | 2017-03-07 |
US10213403B2 (en) | 2019-02-26 |
US20160243072A1 (en) | 2016-08-25 |
US10471031B2 (en) | 2019-11-12 |
US20160263043A1 (en) | 2016-09-15 |
WO2016132217A1 (en) | 2016-08-25 |
WO2016132218A1 (en) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017017729A2 (pt) | forma de dosagem oral de liberação controlada de agonista de receptor gaba | |
GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
CL2017001046A1 (es) | Inhibidoes del bromodominio | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
SG11201609014TA (en) | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy | |
BR112017010440A2 (pt) | administração sublingual de riluzol | |
BR112018005076A8 (pt) | Tratamento final extrativo de uma mistura de metanol-mma que contém sal de sódio | |
PL3487505T3 (pl) | Podawanie i dawkowanie diaminofenotiazyn | |
IL263941B (en) | Sustained-release pregabalin dosage forms | |
BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
IL253011A0 (en) | A novel inhibitory protein of pi3k gamma for the treatment of diseases in the respiratory system | |
BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
SG10202107832UA (en) | Dosage regimen for treatment of solid tumors | |
BR112017022846A2 (pt) | combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes | |
MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
BR112017009358A2 (pt) | imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo | |
CR20160353A (es) | Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
BR112017022856A2 (pt) | combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas | |
CR20170125A (es) | Composición farmacéutica sólica que comprende amlodipina y losartán | |
PL3142641T3 (pl) | Preparaty do leczenia nadczynności tarczycy | |
PH12017500923A1 (en) | New dosage and use of a a2a antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |